C. Mircea S. Tesileanu

Adjuvant and concurrent temozolomide for 1p/19q non-co-deleted anaplastic glioma (CATNON; EORTC study 26053-22054): second interim analysis of a randomised, open-label, phase 3 study

Martin J. van den Bent, C. Mircea S. Tesileanu, Wolfgang Wick et al. · The Lancet Oncology · 2021 · 307 citations · Full text

Surgical Oncology, Health Sciences, Glioma +11

Survival of diffuse astrocytic glioma, IDH1/2 wildtype, with molecular features of glioblastoma, WHO grade IV: a confirmation of the cIMPACT-NOW criteria

C. Mircea S. Tesileanu, Linda Dirven, Maarten M.J. Wijnenga et al. · Neuro-Oncology · 2019 · 207 citations · Full text

Temozolomide and Radiotherapy versus Radiotherapy Alone in Patients with Glioblastoma, <i>IDH</i> -wildtype: <i>Post Hoc</i> Analysis of the EORTC Randomized Phase III CATNON Trial

C. Mircea S. Tesileanu, Marc Sanson, Wolfgang Wick et al. · Clinical Cancer Research · 2022 · 68 citations · Full text

Prognostic significance of genome-wide DNA methylation profiles within the randomized, phase 3, EORTC CATNON trial on non-1p/19q deleted anaplastic glioma

C. Mircea S. Tesileanu, Martin J. van den Bent, Marc Sanson et al. · Neuro-Oncology · 2021 · 59 citations · Full text

Non-IDH1-R132H IDH1/2 mutations are associated with increased DNA methylation and improved survival in astrocytomas, compared to IDH1-R132H mutations

C. Mircea S. Tesileanu, Wies Vallentgoed, Marc Sanson et al. · Acta Neuropathologica · 2021 · 52 citations · Full text